MannKind Corporation (MNKD) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MannKind Corporation (MNKD) closed at USD 3.02 on 2026-10-14, a change of -43 % over the past year, with a market capitalization of USD 1.03B.

MannKind Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MannKind Corporation key figures

Previous close

USD 3.02 (2026-10-14)

1-year change

-43 %

Market cap

USD 1.03B

Enterprise value

USD 1.35B

P/E ratio (trailing)

-21.27

P/E ratio (forward)

25.02

EPS (trailing)

-0.15

EPS (forward)

0.13

PEG ratio

4.39

Price to book

-14.70

Revenue growth

42.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.70

Employees

591

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MannKind Corporation and compare it with other stocks.